Viridian Therapeutics, Inc. completed a public offering of $250 million in convertible senior notes on May 11, 2026, with a 1.75% interest rate, to fund expansion and R&D. They also sold 7.35 million shares at $17 each, raising $117 million, with net proceeds intended for debt repayment and growth initiatives.